2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in

Aisling Capital

WebsiteLinkedInTwittercbCrunchbase
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
    Investment stages
    • Series A
    • Series B
    • Series C
    • Growth
    Industries
    • Therapeutics
    • Biopharmaceuticals
    • Medical Technology
    • Healthcare Products
    • Healthcare Services
    • Life Sciences
    About
    Aisling Capital is a New York-based investment firm focused on backing companies in therapeutics and healthcare products. Their focus spans biopharma, medical technology, and healthcare services across the United States. The firm supports life science companies from Series A through growth stage.
    Min check size
    $1M
    Max check size
    $10M
    Fund size
    NPS

    Investment Thesis

    Aisling Capital is a Series A to growth stage investment firm deploying capital across therapeutics, biopharmaceuticals, medical technology, and healthcare products and services. They invest in companies developing and commercializing differentiated therapeutic assets, with a focus on clinically de-risked programs and platforms addressing significant unmet medical need. The firm differentiates itself through multi-decade, multi-fund continuity in life sciences and deep scientific and transactional expertise across drug development cycles.
    Lead investor
    Co Invest
    Number of exits
    Preferred contact method

    Manager's Experience

    Founded in 2000 by Steve Elms, Andrew Schiff, and Dennis Purcell. Team includes Managing Partners Andrew Schiff, Steve Elms, and Dennis Purcell. Manages $1.9B+ across five funds since inception. Focused on life sciences and healthcare investments across biopharmaceuticals, medical devices, diagnostics, and healthcare services. Portfolio includes companies advancing therapeutics and life science technologies.

    Aisling Capital Contacts Information

    Secondary contact

    Team

    Steven Elms-Managing Partner

    Andrew Schiff-Managing Partner

    Eric Aguiar-Partner

    Aftab Kherani-Partner

    Wonpyo Yun-Principal

    Sunny Reddy-Principal

    Katie Tansey-VP Investor Relations & Marketing

    Robert Wenzel-title unconfirmed

    Portfolio

    Aclaris Therapeutics

    Adams Respiratory Therapeutics

    ADMA Biologics

    Advion

    Aeglea BioTherapeutics

    Agile Therapeutics

    Aimmune Therapeutics

    Ajax Health

    Allos Therapeutics

    Ambit Biosciences

    Antios Therapeutics

    Aragon Pharmaceuticals

    Archimica

    Arcus Biosciences

    ARMGO Pharma

    ARMO BioSciences

    Ascendis Pharma

    Aton Pharma

    Atreca

    Audentes Therapeutics

    Auxilium Pharmaceuticals

    AVANZA Laboratories

    AVROBIO

    Axcan Pharma

    Barrier Therapeutics

    Bicara Therapeutics

    Bioenvision

    Biohaven Pharmaceuticals

    Biomea Fusion

    BridgeBio Pharma

    BridgeBio Oncology Therapeutics

    CalciMedica

    Cardiokine

    Catalent

    Cempra

    Chimerix

    Cidara Therapeutics

    Clovis Oncology

    CollaGenex Pharmaceuticals

    Colorescience

    COMPASS Pathways

    Cynapsus Therapeutics

    Cytos Biotechnology

    Dermira

    Dren Bio

    Durata Therapeutics

    EarLens

    Eidos Therapeutics

    Elevation Oncology

    Esperion Therapeutics

    F2G

    Forge Biologics

    Garuda Therapeutics

    Global Blood Therapeutics

    GondolaBio

    GTx

    Harmony Biosciences

    Infinity Pharmaceuticals

    Intercept Pharmaceuticals

    Intersect ENT

    LENSAR

    Lombard Medical

    Loxo Oncology

    MAP Pharmaceuticals

    Marker Therapeutics

    Medical Knowledge Group

    MEI Pharma

    Menlo Therapeutics

    Mindful Health Solutions

    Miramar Labs

    Monte Rosa Therapeutics

    Myogen

    Nabriva

    NextWave Pharmaceuticals

    Novazyme Pharmaceuticals

    Nuvation Bio

    ObsEva

    Oculex Pharmaceuticals

    OnKure Therapeutics

    Paratek Pharmaceuticals

    PellePharm

    Pernix Therapeutics

    Pharmaron

    Planet Biopharmaceuticals

    Poseida Therapeutics

    PowerVision

    PreCision Dermatology

    Prolacta Bioscience

    Promentis Pharmaceuticals

    Protagonist Therapeutics

    Quintiles Transnational

    Roka Bioscience

    Scholar Rock

    Seragon Pharmaceuticals

    Sirion Therapeutics

    SkinMedica

    Sorrento Therapeutics

    Spirox

    Spruce Biosciences

    Spyre Therapeutics

    Syndax Pharmaceuticals

    Synergy Pharmaceuticals

    Syros Pharmaceuticals

    T2 Biosystems

    Talaris Therapeutics

    Topaz Pharmaceuticals

    TransEnterix

    Treeline Biosciences

    TRIA Beauty

    UroGen Pharma

    Verona Pharma

    Versartis

    ViewRay

    Viracta Pharmaceuticals

    VIVUS

    Wugen

    Zavante Therapeutics

    ZELTIQ Aesthetics

    Zosano Pharma

    Allotera Therapeutics

    Fund number
    Year Founded
    Vintage Year
    Net Internal Rate of Return
    Investment Multiple
    Capital Allocation
    Management Fee
    Carried Interest
    AUM
    Follow-on Investments
    Graduation Rate
    Write-Off Ratio
    Last profile update timestamp